The earnings call presented a mixed view with significant achievements in clinical adoption and potential growth opportunities in MRD, yet faced challenges with revenue decline, biopharma project delays, and gross margin pressures. The company remains confident about future reimbursement outcomes and growth potential.

Company Guidance

During the Personalis Second Quarter 2025 Earnings Conference Call, several key metrics and strategic updates were discussed. The company reported $17.2 million in revenue for the second quarter, reflecting a 24% decrease year-over-year, largely due to declines in revenue from Natera and Moderna. Despite this, the clinical adoption of their NeXT Personal test showed robust growth, with test volumes increasing by 59% sequentially, delivering nearly 3,500 clinical results. The company has expanded its base of ordering physicians to over 600. Personalis is targeting Medicare coverage for two indications by the end of the year, aiming to capture a significant share of the $20 billion MRD market. Full-year revenue guidance was updated to a range of $70 million to $80 million, down from the previous $80 million to $90 million, due to industry-wide headwinds in biopharma R&D spending. The company continues to focus on converting its biopharma pipeline, expecting 300% to 400% growth in MRD-related revenue this year, and anticipates achieving Medicare reimbursement as a significant catalyst for future financial performance.

Accelerated Clinical Adoption

Test volume for NeXT Personal grew 59% sequentially with nearly 3,500 clinical results delivered in Q2, expanding the base of ordering physicians to over 600.

Partnership with Tempus

The partnership with Tempus is gaining momentum, commercializing NeXT Personal across major cancer indications and immunotherapy monitoring.

MRD Market Growth Potential

The MRD market is poised to exceed $20 billion annually, with Personalis positioned to capture a significant share.

Strong Cash Position

The company ended the quarter with $173.2 million in cash and short-term investments, with no significant debt.

Prospective Reimbursement Catalyst

Personalis is on track to secure Medicare reimbursement for 2 indications this year, which is expected to unlock a significant revenue stream.

NeXT Personal Growth with Biopharma

NeXT Personal revenue from biopharma is on track for 300% to 400% year-over-year growth, with new customers expected to generate over $5 million each in revenue this year.

Personalis (PSNL) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

PSNL Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Nov 05, 2025	2025 (Q3)	-0.28 / -	-0.64	―	―	―
Aug 05, 2025	2025 (Q2)	-0.24 / -0.23	-0.24	4.17% (<+0.01)	―
May 06, 2025	2025 (Q1)	-0.25 / -0.18	-0.26	30.77% (+0.08)	―
Feb 27, 2025	2024 (Q4)	-0.28 / -0.23	-0.54	57.41% (+0.31)	―
Nov 06, 2024	2024 (Q3)	-0.35 / -0.64	-0.6	-6.67% (-0.04)	―
Aug 07, 2024	2024 (Q2)	-0.37 / -0.24	-0.5	52.00% (+0.26)	―
May 08, 2024	2024 (Q1)	-0.41 / -0.26	-0.61	57.38% (+0.35)	―
Feb 28, 2024	2023 (Q4)	-0.50 / -0.54	-0.67	19.40% (+0.13)	―
Nov 07, 2023	2023 (Q3)	-0.52 / -0.60	-0.58	-3.45% (-0.02)	―
Aug 08, 2023	2023 (Q2)	-0.54 / -0.50	-0.6	16.67% (+0.10)	―

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

PSNL Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 05, 2025	$5.64	$4.40	-21.99%
May 06, 2025	$4.00	$4.84	+21.00%
Feb 27, 2025	$4.24	$4.14	-2.36%
Nov 06, 2024	$5.58	$4.32	-22.58%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Personalis (PSNL) report earnings?

Personalis (PSNL) is schdueled to report earning on Nov 05, 2025, After Close (Confirmed).

What is Personalis (PSNL) earnings time?

Personalis (PSNL) earnings time is at Nov 05, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is PSNL EPS forecast?

PSNL EPS forecast for the fiscal quarter 2025 (Q3) is -0.28.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing